Federal Register Notice: FDA will hold a public meeting 11/9 entitled “Drug Interactions with Hormonal Contraceptives(HCs): Public Health and Drug Development Implications.” It also offers an opportunity for public comment on the topic. FDA will seek input from experts on the public health concerns associated with use of HCs and interacting drugs that might affect efficacy and safety, pharmacokinetic /pharmacodynamic considerations in designing drug interaction studies with HCs during drug development, and approaches to translating the results of drug interaction information into informative labeling and communication. The input received may be used to refine FDA’s thinking on HC drug interaction study design and interpretation, and labeling communication on drug interaction risk. The meeting will be held from 8:30 a.m. to 4:30 p.m. at the FDA White Oak Campus, 10903 New Hampshire Ave., Bldg. 31 Conference Center, Section A of the Great Room (Rm. 1503), Silver Spring, MD. Contact Christine Le, (301) 796-2398, email: Christine.Le@fda.hhs.gov. To view this notice, click here.